Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2718384 | 0.86 | POLB (0.32) | ALDH1A1MAPTMPO | |
| SCHEMBL2718388 | 0.86 | POLB (0.32) | ALDH1A1MAPTMPO | |
| SCHEMBL2717906 | 0.81 | MEN1 (0.34) | ERN1ALDH1A1 | |
| SCHEMBL20482139 | 0.68 | KDM4E (0.37) | ERN1ALDH1A1KDM4E | |
| SCHEMBL2717541 | 0.67 | USP2 (0.36) | ALDH1A1KDM4EMAPT | |
| SCHEMBL2717538 | 0.67 | USP2 (0.36) | ALDH1A1KDM4EMAPT | |
| SCHEMBL20295181 | 0.66 | ALDH1A1 (0.46) | ALDH1A1KDM4EMAPT | |
| SCHEMBL15428225 | 0.65 | CA12 (0.40) | ALDH1A1KDM4EMAPT | |
| SCHEMBL30134885 | 0.65 | CA12 (0.40) | ALDH1A1KDM4EMAPT | |
| SCHEMBL1665856 | 0.65 | MAPT (0.38) | ERN1ALDH1A1KDM4ETYRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2635565-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | Amgen Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061696-A1 | 5 -CYANO-4, 6 -DIAMINOPYRIMIDINE OR 6 -AMINOPURINE DERIVATIVES AS PI3K- DELTA INHIBITORS | AMGEN INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031355-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, SSB, MALT1 | ERN1 4384/4885ALDH1A1 3702/4885KDM4E 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.